Scalp reduction

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

Retrieved on: 
Tuesday, February 21, 2023

Arcutis recognizes the urgent need for a new therapy that could enable symptom control, easier management, and increased adherence,” said Patrick Burnett M.D., Ph.D, F.A.A.D., Chief Medical Officer at Arcutis.

Key Points: 
  • Arcutis recognizes the urgent need for a new therapy that could enable symptom control, easier management, and increased adherence,” said Patrick Burnett M.D., Ph.D, F.A.A.D., Chief Medical Officer at Arcutis.
  • “Roflumilast foam, which is being developed as an easy-to-use, steroid free, once-daily topical treatment, has been shown in clinical trials to be effective and well tolerated.
  • “There has not been a once-daily steroid-free topical prescription treatment approved for seborrheic dermatitis in over a decade.
  • The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a Phase 3, parallel group, double blind, vehicle-controlled study evaluating the safety and efficacy of roflumilast foam 0.3%.

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Friday, September 9, 2022

Roflumilast foam demonstrated strong efficacy across multiple endpoints, including 50% of individuals with seborrheic dermatitis achieving IGA clear at week 8.

Key Points: 
  • Roflumilast foam demonstrated strong efficacy across multiple endpoints, including 50% of individuals with seborrheic dermatitis achieving IGA clear at week 8.
  • Roflumilast foam also demonstrated statistically significant improvements compared to vehicle on all secondary endpoints in the trial, including itch, scaling, and erythema (redness).
  • (63.6% with roflumilast foam vs 42.3% vehicle (P=0.0002))
    More than 50% of individuals treated with roflumilast foam achieved an erythema score of 0 at week 8.
  • Roflumilast foam is a once-daily topical foam formulation of roflumilast which the Company is developing for both seborrheic dermatitis and scalp and body psoriasis.

Hims & Hers Now Offering a Dual-Action Topical Hair Loss Treatment for Men

Retrieved on: 
Wednesday, June 2, 2021

The Topical Finasteride & Minoxidil Spray is a pill-free prescription alternative to traditional oral finasteride treatment that provides effective support for male pattern hair loss.

Key Points: 
  • The Topical Finasteride & Minoxidil Spray is a pill-free prescription alternative to traditional oral finasteride treatment that provides effective support for male pattern hair loss.
  • The latest in a long list of high quality personalized wellness treatments available through the Hims & Hers telehealth platform, the combination of ingredients is specifically formulated to stop hair loss and regrow hair.
  • With the addition of prescription Topical Finasteride & Minoxidil Spray, Hims is a leader in providing customizable offerings for hair loss in men, said Hims & Hers Chief Medical Officer Dr. Patrick Carroll.
  • Hims suite of hair loss products can provide a high level of personalization for men who are seeking the optimal treatment for their own hair loss journey.

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting

Retrieved on: 
Monday, February 24, 2020

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from its CTP-543 Phase 2 dose-ranging trial in alopecia areata have been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 20-24, 2020, in Denver, CO.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from its CTP-543 Phase 2 dose-ranging trial in alopecia areata have been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 20-24, 2020, in Denver, CO.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543 for alopecia areata.
  • Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body.
  • The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.